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Background: With the rapid development of “-omic” technologies, an increasing number of purported biomarkers
have been identified for cancer and other diseases. The process of identifying those that are most promising and
validating them for use at the population level for prevention and early detection is a critical next step in achieving
significant health benefits.
Methods: In this paper, we propose that in order to effectively translate biomarkers for practical clinical use, it is
important to distinguish and quantify the differences between the use of biomarkers and other risk factors to identify
preventive interventions versus their use in disease risk prediction and early detection. We developed mathematical
models for quantitatively evaluating risk and benefit in use of biomarkers for disease prevention or early detection. Simple
numerical examples were used to demonstrate the potential applications of the models for various types of data.
Results: We propose an index which takes into account potential adverse consequences of biomarker-driven
interventions – the ‘naïve’ ratio of population benefit (RPB) – to facilitate evaluating the potential impact of
biomarkers on cancer prevention and personalized medicine. The index RPB is developed for both binary and
continuous biomarkers/risk factors. Examples with computational analyses are presented in the paper to contrast
the differences in using biomarkers/risk factors for prevention and early detection.
Conclusions: Integrating epidemiologic knowledge into clinical decision making is a key step to translate new
biomarkers/risk factors into practical use to achieve health benefits. The RPB proposed in this paper considers
the absolute risk of a disease in intervention, and takes into account the risk-benefit effects simultaneously for a
marker/exposure at the population level. The RPB illustrates a unique approach to quantitatively assess the risk
and potential benefits of using a biomarker/risk factor for intervention in both early detection and prevention.
Keywords: Ratio of population benefit, RPB, Biomarkers, Disease prevention, Disease early detection, Clinical
decision making, Biomarkers for early detection, Risk/benefit analysisBackground
The identification of robust cancer risk factors and
biomarkers are the cornerstones of modern approaches
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number of environmental and host risk factors (either
inherited or somatic) have been identified that are
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cer incidence and mortality is still a major challenge. The
process of selecting and evaluating the most promising
biomarkers for clinical application among the large number
of purported biomarkers is a critical step in the translation
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prevention programs versus disease risk prediction andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Li et al. BMC Medical Informatics and Decision Making 2014, 14:15 Page 2 of 12
http://www.biomedcentral.com/1472-6947/14/15early detection. Quantitative analysis of these differences
can facilitate the translational process.
Pepe et al. [1] compared the association of a marker
with a disease, often quantified in case-control or cross-
sectional studies by the odds ratio (OR), with use of the
marker for disease classification (i.e. presence or absence
of cancer in a sample), and illustrated the limitation of
the OR in gauging the performance of a diagnostic,
prognostic, or screening marker. More recently, the use
of markers discovered in genetic association studies for
disease risk prediction was specifically addressed by
Jakobsdottir et al. [2]. The limitations of using markers
for medical diagnosis or early detection also have been
comprehensively assessed [3-5]. Recently, an increasing
number of studies have focused on the use of previously-
identified risk factors and biomarkers (e.g., one or more
constitutive SNPs (single-nucleotide polymorphism)) for
cancer prevention or for pathway-targeted therapy develop-
ment [6,7]. In practice, the specific criteria for evaluating a
biomarker or risk factor for disease detection/prediction
could be quite different than that for disease prevention.
To highlight and evaluate these differences quantitatively,
we first illustrate the numerical relationship between the
OR of a biomarker/risk factor and its population attribut-
able risk percent (PAR%) (assuming causality) in the con-
text of a population prevention program. We then illustrate
the corresponding accuracy, as measured by sensitivity and
specificity, for a biomarker/risk factor with identical charac-
teristics (OR and prevalence) in the context of a disease
detection/prediction program. Finally we propose an
index – the ‘naïve’ ratio of population benefit (RPB) – for
quantifying overall risk/benefit of using a biomarker for
cancer prevention or detection/prediction at the popula-
tion level. Analyses are presented separately for binary
and continuous biomarkers.
Methods and results
Numerical relationships between sensitivity, specificity
and population attributable risk for binary and
continuous biomarkers
Calculation for binary marker/risk factor
The PAR% is often used to estimate the fraction of the
total disease burden in the population that would not
have occurred if a causal risk factor were absent [8]. To
help introduce the latter parts of the paper, we first
illustrate the numerical relationships between PAR% for
causal binary markers/risk factors at different prevalence
and relative risk levels and the corresponding sensitivity
and specificity of using a marker/risk factor with identi-
cal characteristics for disease classification/prediction
(Table 1). The status of a specific binary risk factor (e.g.
a mutated gene or exposure) and the observed disease
outcome status, also binary, can be displayed as a stand-
ard 2 × 2 contingency table, with the four cells labeleda(+/+), b(+/-), c(-/+) and d(-/-) corresponding to the
counts of individuals in a cohort with status of exposure
and outcome (+ for yes, - for no), respectively. If out-
come is directly predicted by the marker, for calculation
of sensitivity and specificity (either for screening or
screening-based disease intervention), the data can be
arranged in an identical 2 × 2 table with the individual
cells labeled a (true positive), b (false positive), c (false
negative) and d (true negative) relating the biomarker
status with a true outcome status or “gold standard”.
Using the counts in the four cells of the contingency
table (whether corresponding to exposure and outcome
or disease classification) several commonly used quan-
tities can be obtained. A binary marker/risk factor has
two possible values, leading to fixed sensitivity (a/(a + c))
and specificity (d/(b + d)) values in a population with a
specific OR and marker prevalence, in which the inci-
dences in exposed (or marker carriers) and unexposed
(or marker non-carriers) are a/(a + b), c/(c + d) respectively.
Table 1 shows the numerical relationships among i) preva-
lence of a risk factor/marker, ii) the relative risk of disease
associated with the marker (indicated by OR), iii) PAR%, iv)
sensitivity, and v) specificity. If we let r1 = ((a + c)/(a + b +
c + d)), r2 = c/(c + d), (r1 is the prevalence and r2 is the false
negative fraction), the population attributable risk can be
calculated as PAR%= (r1 - r2)/r1100%. By definition, the
false positive fraction = 1-specificity; the false negative
fraction = 1-sensitivity; and the OR = (sensitivity/(1-
sensitivity))/((1-specificity)/specificity). In Table 1, ma-
rker prevalence and risk factor exposure prevalence are
interchangeable algebraically; the former used for early
detection and risk prediction, and the later used for preven-
tion. The calculation of PAR% above was based on the
assumption of no adjustment for potential confounders. A
common way to obtain PAR% adjusted for confounders is




where pi is the proportion of cases in stratum i, PARi%
is the PAR% estimated from stratum i. More details
for dealing with confounders can be found in Rothman
et al. [9].
Numerical analysis for continuous marker/risk factor
Pepe et al. [1] evaluated the limitation of the OR in
gauging the performance of a diagnostic, prognostic, or
screening marker. Illustrated here is the use of continu-
ous biomarkers both for diagnostic/prognostic/screening
and for prevention, along with the relationship between
the OR value and PAR% parameters for the continuous
markers. Figure 1 presents a few hypothetical normal
distributions of continuous markers/risk factors with dif-
ferent OR risk values.
For the continuous distribution markers, the sensi-
tivity and specificity can be calculated as follows [10],
Table 1 Numerical illustration for calculating RPB of hypothetical binary markers using data of three cancers as examples
Biomarker/exposure characteristics Ratio of population benefit (RPB) Net benefit (NB)
OR Prevalence (%) PAR
%
Sen. Spe. RPB RPB RPB NB NB NB
(EA, f 0.03) (Breast ca, f 0.06) (Ovarian ca, f 0.15) (EA, f 0.03) (Breast ca, f 0.06) (Ovarian ca, f 0.15)
1.5 0.1 0.05 0.001 0.999 −0.000 −0.001 −0.001 −0.000 −0.000 −0.000
2 0.1 0.10 0.002 0.999 −0.000 −0.001 −0.001 −0.000 −0.000 −0.000
4 0.1 0.29 0.004 0.999 0.000 −0.000 −0.001 0.000 −0.000 −0.000
10 0.1 0.81 0.009 0.999 0.002 0.001 −0.000 0.000 0.000 −0.000
20 0.1 1.56 0.017 0.999 0.004 0.002 0.000 0.000 0.000 0.000
50 0.1 3.19 0.033 0.999 0.008 0.004 0.001 0.000 0.000 0.000
1.5 1 0.49 0.015 0.990 −0.004 −0.006 −0.008 −0.000 −0.000 −0.001
2 1 0.97 0.020 0.990 −0.002 −0.006 −0.008 0.000 −0.000 −0.001
4 1 2.81 0.038 0.990 0.002 −0.003 −0.007 0.000 −0.000 −0.001
10 1 7.61 0.085 0.991 0.015 0.004 −0.003 0.001 0.000 −0.001
20 1 13.93 0.148 0.991 0.031 0.014 0.001 0.001 0.001 0.000
50 1 26.33 0.271 0.993 0.063 0.033 0.010 0.002 0.002 0.002
1.5 10 4.70 0.142 0.900 −0.039 −0.065 −0.084 −0.002 −0.004 −0.013
2 10 8.94 0.180 0.901 −0.029 −0.059 −0.082 −0.001 −0.004 −0.013
4 10 22.54 0.303 0.902 0.003 −0.040 −0.073 0.000 −0.003 −0.012
10 10 46.05 0.514 0.904 0.058 −0.008 −0.057 0.002 −0.001 −0.009
20 10 63.92 0.675 0.906 0.100 0.017 −0.046 0.004 0.001 −0.007
50 10 81.79 0.836 0.907 0.141 0.041 −0.034 0.006 0.003 −0.005
1.5 30 12.90 0.390 0.701 −0.125 −0.200 −0.256 −0.005 −0.014 −0.041
2 30 22.80 0.460 0.702 −0.107 −0.189 −0.251 −0.004 −0.013 −0.040
4 30 46.84 0.628 0.703 −0.064 −0.163 −0.238 −0.003 −0.011 −0.038
10 30 72.43 0.807 0.705 −0.017 −0.136 −0.225 −0.001 −0.009 −0.036
20 30 84.69 0.893 0.706 0.005 −0.123 −0.219 0.000 −0.009 −0.035
50 30 93.44 0.954 0.707 0.021 −0.114 −0.215 0.001 −0.008 −0.034
1.5 70 25.71 0.777 0.301 −0.327 −0.486 −0.606 −0.013 −0.034 −0.096
2 70 40.89 0.823 0.301 −0.316 −0.480 −0.603 −0.013 −0.033 −0.096























Table 1 Numerical illustration for calculating RPB of hypothetical binary markers using data of three cancers as examples (Continued)
10 70 86.14 0.958 0.303 −0.280 −0.459 −0.593 −0.011 −0.032 −0.094
20 70 92.92 0.979 0.303 −0.275 −0.456 −0.591 −0.011 −0.032 −0.094
50 70 97.13 0.991 0.303 −0.272 −0.454 −0.591 −0.011 −0.031 −0.094
ca= cancer. EA= esophageal adenocarcinoma. f= loss adjustment factor of quality-adjusted life year. NB= net benefit. OR= odds ratio.
The table shows numerical relationship between Odds ratio, Marker prevalence, PAR% of binary markers and their RPB based on the cancer data of three studies. NB were also calculated.
The table assumes 1% disease prevalence in general population. For PAR%, sensitivity and specificity similar patterns are observed with other disease prevalence values less than about 10%. Disease prevalence affects























Figure 1 Hypothetical distribution patterns of continuous markers with different relative risks, and thresholds for risk prediction.
Two normal distributions (mean = 0 and standard deviation = 0.5) are used to represent the distribution of a continuous marker in disease (solid
curved line) and non-disease (dashed curved line) populations for six different ORs. The locations of the means for the disease population are
consistent with the logit model Pr(D = 1|X) = α + βX, in which one unit increase corresponds to the OR shown in the figure. The three vertical
bars (solid, dotted, and dashed) correspond to different thresholds (cut off value ‘c’) for positive-negative calls of a disease with a continuous
distribution marker. Specifically, the solid bar represents the threshold value c such that the sensitivity is kept for 0.95 for various OR values in the
plot; the dotted bar represents the threshold value c such that the sensitivity and specificity are equal for various OR values in the plots; and the
dashed bar represents the threshold value c such that the specificity is kept for 0.95 for various OR values in the plot. The examples of using the
continuous marker for disease classification or prevention are shown in Figure 2; and corresponding sensitivity, specificity and PAR% of various
thresholds (three bars in this Figure) are shown in Table 2 and Figure 2 (the cross, circle, and triangle in Figure 2 correspond to solid, dashed,
and solid vertical bars in Figure 1).
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, where D indicates non-disease group, and c
is the threshold above which a positive (disease) call
will be made. In contrast to binary markers, which only
have one set of sensitivity and specificity values, con-
tinuous markers can be used to generate infinite sets of
sensitivity and specificity values depending on the
threshold value of c.
To quantify PAR% for continuous markers, let w be the
proportion of diseased individuals in a population or risk of
a disease in the general population, then for a marker with
a continuous value, a specific set of sensitivity and specifi-
city is obtained for a given threshold c, the risk of ‘unex-
posed’ (the proportion of subjects, either diseased or non-
diseased whose marker level is lower than the threshold c)








f d xð Þdxþw½1−
R ∞
c
f d xð Þdx
¼ w 1−sensitivitycð Þ1−wð Þspecificitycþw 1−sensitivitycð Þ ,
where fd(x) and f d xð Þ are the probability density dis-
tribution of a biomarker in the diseased and non-
diseased group respectively (assuming normal distribu-
tion), sensitivityc and specificityc are the sensitivity and
specificity of the continuous marker at threshold c.
Therefore, for a continuous marker, we have PAR% =
(w – que)/w. Table 2 shows the numerical relationshipsamong sensitivity and specificity and PAR% of the
quantification for various thresholds c in Figure 2.Distinguishing the use of biomarkers/risk factors for cancer
detection and prevention
Above we presented the numerical relationships between
sensitivity, specificity and PAR% for binary and continu-
ous biomarkers (Tables 1 and 2). Below we use examples
to illustrate the importance of distinguishing between
the use of biomarkers for cancer detection/risk predic-
tion and for cancer prevention since the consequences
of false positive and false negative findings may differ
substantially in these two contexts.
Example 1: Genotype and bladder cancer. A genetic
association study [11] showed strong evidence that the
copy number of gene GSTM1 is significantly associated
with risk of bladder cancer, with an OR = 1.9 corre-
sponding to the GSTM1 null genotype (51% prevalence).
If this marker were used as a binary marker for bladder
cancer detection in the general population, it would
result in 66% sensitivity and 50% specificity, a poor
marker for diagnostic purposes. However, if a drug were
to be developed that targeted the pathway(s) by which
GSTM1 null increases risk, and if the drug were 100%
effective in preventing bladder cancer without toxic side
effects (and ignoring costs), then treatment of all marker
carriers would reduce bladder cancer by 31% (PAR%),
Table 2 Numerical illustration for calculating RPB of hypothetical continuous markers using data of three cancers
as examples
Biomarker/exposure characteristicsa Ratio of population benefit (RPB) Net benefit (NB)
(Threshold)b OR PAR% Sen. Spe. RPB RPB RPB NB NB NB
(EA, f 0.03) (Breast ca, f 0.06) (Ovarian ca, f=0.15) (EA, f=0.03) (Breast ca, f=0.06) (Ovarian ca, f=0.15)
Fixed sensitivity
(95%)
1.5 33.22 0.95 0.07 −0.456 −0.659 −0.812 −0.018 −0.046 −0.129
2 48.88 0.95 0.09 −0.440 −0.641 −0.792 −0.017 −0.045 −0.126
4 71.30 0.95 0.16 −0.389 −0.583 −0.728 −0.015 −0.040 −0.115
10 84.46 0.95 0.29 −0.287 −0.466 −0.601 −0.011 −0.032 −0.095
20 89.01 0.95 0.43 −0.187 −0.352 −0.475 −0.007 −0.024 −0.075
50 92.25 0.95 0.61 −0.051 −0.196 −0.305 −0.002 −0.014 −0.048
Fixed specificity
(95%)
1.5 2.59 0.08 0.95 −0.019 −0.032 −0.043 −0.001 −0.002 −0.007
2 4.95 0.10 0.95 −0.013 −0.029 −0.041 −0.001 −0.002 −0.007
4 12.67 0.17 0.95 0.006 −0.018 −0.036 0.000 −0.001 −0.006
10 27.40 0.31 0.95 0.041 0.002 −0.028 0.002 0.000 −0.004
20 41.15 0.44 0.95 0.074 0.021 −0.019 0.003 0.001 −0.003
50 60.16 0.62 0.95 0.119 0.047 −0.008 0.005 0.003 −0.001
Balanced sensitivity
& specificityc
1.5 14.83 0.54 0.54 −0.208 −0.316 −0.397 −0.008 −0.022 −0.063
2 23.89 0.57 0.57 −0.178 −0.285 −0.366 −0.007 −0.020 −0.058
4 42.57 0.64 0.63 −0.114 −0.222 −0.304 −0.005 −0.015 −0.048
10 60.28 0.72 0.72 −0.030 −0.137 −0.218 −0.001 −0.010 −0.035
20 70.68 0.78 0.77 0.024 −0.085 −0.166 0.001 −0.006 −0.026
50 80.17 0.84 0.84 0.088 −0.020 −0.101 0.003 −0.001 −0.016
Numerical relationships between Odds ratio and PAR% of continuous markers and their RPB based on the data of three studies.
ca= cancer. EA= esophageal adenocarcinoma. f = loss-adjustment factor of quality-adjusted life year. NB= net benefit.
OR= odds ratio. Sen.= sensitivity, Spe.= specificity.
The disease prevalence of population used for the table = 0.01. As shown in the formula of RPB for continuous markers, disease prevalence w will directly affect
the value of RPB.
aHypothetical continuous biomarker/exposure with assumed distributions as described in Figure 1.
bThreshold used for continuous biomarkers positive are the thresholds shown in Figure 1 (three vertical bars).
cUsing a threshold that lead to sensitivity and specificity closest to the upper left corner of ROC curve coordinates for cutoff.
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fit. One way to quantify such a benefit can be performed
using the method developed in this paper as shown in
example 4.
Example 2: Smoking and lung cancer. Using Table 1, if
the prevalence of smoking (risk factor) in a population is
30%, and the OR of smoking for lung cancer risk is esti-
mated to be 10- to 20-fold higher than the non-smokers,
then the corresponding PAR% value is 73-85% (had all
smokers not smoked, there would have been 73% to 85%
fewer lung cancers). The corresponding false positive
fraction is about 29.3%, which indicates among the non-
lung cancer group (normal), 29.3% are smokers. This
high ‘false positive’ fraction may be tolerable for lung
cancer prevention since reducing 73-85% of lung cancers
at the ‘expense’ of abstaining from smoking is likely ac-
ceptable. (If other diseases caused by smoking are con-
sidered, this argument is even stronger). Quantificationof such benefit can be accomplished using the method
developed in this paper as shown in example 3.
Quantitative evaluation of the benefit of using
biomarkers for disease detection/prediction and disease
prevention at the population level
The above numerical analyses and specific examples indi-
cate that traditional measures of association (OR, PAR%,
sensitivity, specificity, and others) can have dramatically dif-
ferent implications depending on whether they are applied
to risk prediction, early detection or prevention of disease.
Since false positive and false negative classifications are un-
avoidable in practice [12], we propose an index, the ‘naïve’
ratio of population benefit (RPB), which takes into account
the adverse effects of misclassification, for evaluating the
impact of using biomarkers for early detection/risk predic-
tion and preventive interventions on a disease at the popu-
lation level. Unlike OR, PAR%, sensitivity, specificity, and
Figure 2 Disease prediction performance evaluated by ROC curves
for the hypothetical continuous markers with different relative
risks. ROC curves for continuous risk marker with different odds ratios
(from bottom to top OR = 1.5, 2, 4, 10, 20, 50), which corresponding to
the distribution plots of continuous markers shown in Figure 1. The
crosses correspond to a fixed sensitivities; the circles to a fixed
specificities; and triangles to equal sensitivities and specificities.
Their corresponding PAR% values are shown in Table 2.
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disease prevalence, the RPB does account for disease preva-
lence in a reasonable way as shown in the following parts
of the paper. This new index is not intended for evaluating
or comparing the prediction accuracy of biomarkers or pre-
diction models; instead it is intended for analyzing the po-
tential benefit for a population using a previously-selected
biomarker for disease intervention after taking into account
potential adverse effects.
RPB for binary markers/risk factors
Using the 2 × 2 contingency table introduced earlier, if no
biomarker is used for early cancer detection/cancer risk
prediction, lethal cancer cases will occur (a + c); with a
subset of individuals (b + d ) remaining cancer free. The
quantification of lives lost in this situation is − f1 ∗ (a + c),
and lives gained is f2 ∗ (b + d), with the negative sign in-
dicating loss; (− f1 represents naïve quantification of
lives lost due to cancer cases discovered at a late incur-
able stage), a positive value, f1 represents lives gained if
cancer is detected early, and f2 represents naïve quanti-
fication of lives gained due to non-cancer subjects who
are not classified as cancer (gain due to perfect markers
with no false positives and − f2 represents loss due to a
false positive call). If a binary biomarker is used for
cancer detection, then let a be the cancer cases that will
be detected earlier (true positive), and b be the number
of non-cancer cases are classified as cancer due to false
positives associated with this biomarker. The sum ofgains and losses associated with this biomarker is f1a +
(−f1c) + (−f2b) + f2d. Note, the sum of losses and gains
associated with not using the biomarker − f1(a + c) + f2
(b + d); hence, the change of total net gain for compari-
son using a biomarker vs. no biomarker is f1a − f2b, (no
change for − f1c + f2d when comparing the two sums,
assuming false negative calls c will be treated the same
as no biomarker). For a population, if all cancer cases
could be detected early without false positives (an ideal
marker), the sum of gains and losses for the population
is f1 ∗ (a + c) + f2 ∗ (b + d). Therefore, assuming binary
biomarkers for cancer detection are not perfect (with
false positives and false negatives), a naïve estimation
of the ratio of population benefit (RPB) can be esti-
mated by RPB ¼ f 1a−f 2b
f
1 aþcð Þþf 2 bþdð Þ










Note that changes in disease prevalence are accounted
for in the RPB calculation, which uses all of the terms
defining prevalence (a + c)/(a + b + c + d). The RPB is
different from Net Benefit (NB) based on decision
curve analysis [13,14]. NB = (a−wb)/(a + b + c + d),
where w is the weight for counting the cost of false
positive relatives to the cost of false negatives. The de-
nominator of NB counts the cost of the overall popula-
tion, whereas the denominator of RPB only counts the
cost for worst possible performance of a marker i.e. the
counts for true positive a and true negative d both are 0 in
prediction. In addition, RPB also considers adverse effect
(δ) due to intervention as shown in the next section. There-
fore, RPB is more sensitive in evaluating false positive or
false negative costs compare to NB. The adjusted RPB for
potential confounders can also be obtained by the
weighted average of individual RPB for each strata in
stratified analysis, a similar idea to the adjusted PAR%




aif 1 i−bif 2 i
aif 1iþbif 2 iþcif 1iþdif 2i
,
where pi is the proportion of cases in stratum i, and ai,
bi, ci, di, f1i, and f2i are same as in RPB above but are
estimated from specific stratum i. RPB is a percentage
of net gain, which is a ratio of net gains in the group
of marker carriers (or risk factor exposed), including
diseased and non-diseased, against overall gain esti-
mated by quantifying the losses and gains due to false
positive, false negative, true positive and true negative.
Disease prevalence is considered in RPB calculation.
For cancer prevention with consideration of adverse
effects (i.e. prevention measure is applied to the carriers
of a predictive (or risk-causal) biomarker or those ex-










similarly, f1 and f2 are defined as the same as the binary
marker mentioned above; η represents the efficacy of a
prevention measure (i.e. the percentage of cancer re-
duced due to a prevention measure); and δ represents
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fect of a drug for cancer prevention). When there is no ad-
verse effect from a prevention measure, δ = 0. Numerically,
RPB could be negative, 0 or positive, which indicates detri-
mental, neutral, or beneficial overall effects at the popula-
tion level, respectively. In addition, the absolute gain for
early cancer detection or cancer prevention may be quanti-
fied as (af1 - bf2) – h(a + b), and (aηf1 - aδ - bδ) – h(a + b)
respectively, where h is the coefficient for the cost of preven-
tion or treatment of exposed subjects or subjects positive
for specific markers. Following are two examples illustrat-
ing the use of RPB for binary markers and risk factors.
Example 3: Smoking and lung cancer. Since there are
no negative health effects due to abstaining from smok-
ing, we set δ = 0, and RPB becomes aηf1/(af1+ bf2 + cf1+
df2), where η in the example represents efficacy (%) of
lung cancer reduction due to abstaining from smoking.
Example 4: Genotype and bladder cancer. GSTM1 is a
bladder cancer associated biomarker (marker prevalence =
51%, OR = 1.9). If a drug were developed that targeted the
effect associated with the null GSTM1 variant, and if all
carriers of the risk variant were treated with the drug, the
drug had no adverse side effects and is 100% effective (δ= 0,
η= 1), then RPB = af1/(af1+ bf2 + cf1+ df2). However, if the
efficacy of a drug η is much less than 1 and/or the drug has
adverse effects (δ > 0), then RPB will be smaller or even
could become negative. In practice, properly quantifying f1
and f2 may be very complex. However, if the analyses of the
efficacy of the drug for cancer prevention and early detec-
tion are only limited to the diseased group (ignore b and d
and f1≠0) then RPB is equal to the marker’s sensitivity multi-
plied by ηf 1−δð Þ
f 1
.
Example 5: CNV and neuroblastoma. A copy number
variation associated with neuroblastoma was reported re-
cently [15]. The prevalence of the marker (1q21.1) in the
general population is about 9%, and the OR of the marker
(copy loss) for neuroblastoma risk is estimated to be around
3. If this marker were dichotomized as a binary marker for
predicting the absence or presence of the disease, it will
result in a 23% sensitivity and 91% specificity, with a PAR%
of approximately 15%, which indicates the marker could
account for about 15% of neuroblastoma risk if the disease
is truly caused by the CNV (copy-number variation). As-
sume a drug is developed that targeted this marker (1q21.1)
for prevention. If the drug is 100% effective in disease pre-
vention and had no side effects and all persons who were
carriers for the marker were treated with the drug, it would
reduce the total disease cases by 15% (PAR%). However, in
the more likely scenario, drugs have significant side effects
and are not 100% effective such that more extensive risk
benefit analyses are needed. The RPB proposed in this
paper could be used for quantifying and evaluating the
feasibility for population intervention in such a case.Example 6: RPB calculation for three cancers for bin-
ary markers or risk factors. The utility weights for
quality-adjusted life years have been estimated for surgi-
cal treatment of esophageal adenocarcinoma [16], breast
cancer [17], and ovarian cancer [18]; these are 0.97; 0.94;
and 0.85 respectively. The corresponding adjustment
factors for loss of quality of life (f2) are 0.03, 0.06, and
0.15 respectively for the three cancers. If a cancer were
detected early and intervention were a complete success,
this would lead to a benefit value of 1 (true positive
detected early); if a subject were wrongly diagnosed with
cancer and surgery was done, the cost value can be repre-
sented as the loss adjustment factor for quality-adjusted
life year. This leads us to have f1 = 1, f2 = loss-adjustment
factor of a disease intervention to calculate RPB proposed
above. Using breast cancer as an example, f2 = 0.06, since
RPB ¼ af 1−bf 2af 1þbf 2þcf 1þdf 2 ¼
a1−b0:06
a1þb0:06þc1þd0:06 , where a, b,
c, and d are the number of true positive, false positive,
false negative, and true negative due to using a biomarker
for disease outcome prediction for intervention. In many
cases, the OR has been estimated for a marker or risk fac-
tors. In Table 1, we show the relationship among RPB and
various ORs and prevalence of a marker or risk factor
using the loss-adjustment factors of the three cancers as
examples. We also calculated net benefit (NB) values
under these scenarios for comparison. For instance, from
Table 1, if a biomarker has 1% prevalence with OR 10 for
breast cancer risk, then the RPB = 0.004, if OR = 20, RPB =
0.014. If a biomarker has 10% prevalence with OR 10, then
the RPB = -0.008; if OR = 20, RPB = 0.017. It will be possible
to apply these principles to other diseases, novel risk assess-
ments and new treatments as additional data become
available. Table 1 shows numerical examples with the as-
sumption of 1% disease prevalence. Disease prevalence
of a population will directly affect RPB as the a and c
in the 2×2 table are used in the calculation of RPB. For
instance, if disease prevalence is changed from 1% to
3%, and assuming a biomarker (or exposure) preva-
lence of 30%, the RPB for a risk biomarker with various
OR values 1.5, 2, 4, 10, 20, and 50 will be: 0.05, 0.086,
0.172, 0.266, 0.311, 0.345 respectively for EA; -0.064, -0.04,
0.02, 0.084, 0.116, 0.139 respectively for breast cancer;
and -0.18, -0.167, -0.134, -0.099, -0.082, -0.069 respect-
ively for ovarian cancer.RPB for continuous markers and risk factors
For a continuous marker, the ‘naïve’ ratio of popula-
tion benefit for early cancer detection (present or




f d xð Þdx− 1−wð Þf 2
R ∞
c




f d xð Þdxþ 1−wð Þf 2
R ∞
c
f d xð Þdxþwf 1
R c
−∞
f d xð Þdxþ 1−wð Þf 2
R c
−∞
f d xð Þdx
,
where w is disease prevalence in a population, fd(x) and
f d xð Þ are the probability density distribution of a
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spectively and c is the cutoff threshold for positive and
negative calls for a continuous marker. This formula can
also be modified to address potential confounding factors
using stratified analysis. The adjusted RPB for a con-







f d i xð Þdx− 1−wið Þf 2i
R ∞
c




f di xð Þdxþ 1−wið Þf 2i
R ∞
c
f d i xð Þdxþwif 1i
R c
−∞
f di xð Þdxþ 1−wið Þf 2i
R c
−∞
f d i xð Þdx
,
where pi is the proportion of cases in stratum i, and the
quantification for loss f1i, and f2i are the same as in RPB
above but are estimated in specific stratum i. The density
distribution functions fdi(x) and f di xð Þ are the density
distributions of a biomarker in the disease and the
non-disease group respectively in stratum i.Similar to
binary markers, the ‘naïve’ ratio of population benefit for
cancer prevention using continuous markers with consider-




η xð Þf d xð Þdx−w
R ∞
c
δ xð Þf d xð Þdx− 1−wð Þ
R ∞
c




f d xð Þdxþ 1−wð Þf 2
R ∞
c
f d xð Þdxþ wf 1
R c
−∞
f d xð Þdxþ 1−wð Þf 2
R c
−∞
f d xð Þdx
,
where η(x) is efficacy (as a function of x) of a prevention
measure and δ(x) represents adverse effect due to a preven-
tion measure. Similar calculations can be used to obtain
RPB if δ(x) and η(x) are dependent on fd(x) and f d xð Þ. The
total lives gained for early cancer detection and cancer pre-
vention using a continuous marker may be quantified as
wf 1
R ∞
c f d xð Þdx− 1−wð Þf 2
R ∞




c f d xð Þdxþ

1−wð ÞR ∞c f d xð ÞdxÞ , and wf 1
R ∞





xð Þdx− 1−ð wÞ R ∞c δ xð Þf d xð ÞdxÞ−h w
R ∞
c f d xð Þdxþ

1−ð wÞR ∞
c f d xð ÞdxÞ , respectively. As defined for binary markers
above, h is the coefficient for quantification of the cost of
prevention or treatment for exposed subjects or subjects
with positive markers; the other parameters remain the
same as defined for binary markers. For example, BMI
(body mass index) is a continuous marker [19]; studies
have shown the association between high BMI and
esophageal adenocarcinoma risk [20-22]. If this is a
causal association, then BMI may not be a robust
marker for detecting presence or absence of disease.
However, if BMI were considered as a modifiable risk
factor, then false positives may be tolerable since redu-
cing BMI for those people who would never develop
esophageal adenocarcinoma had their BMI not been re-
duced will likely not have substantial detrimental effects
(δ= 0, RPB always >0). If we use BMI ≥30 as the threshold
c and assumed no negative effect (δ = 0) for reducing








f d xð Þdxþ 1−wð Þf 2
R ∞
c
f d xð Þdxþwf 1
R c
−∞
f d xð Þdxþ 1−wð Þf 2
R c
−∞
f d xð Þdx
;
where η(x) is the efficacy of cancer reduction by reducing
BMI, fd(x) and f d xð Þ are the BMI distribution in a specific
at risk population and low risk population, respectively.
However, if negative effects occur when reducing BMI(δ > 0), e.g., if a medication used for weight loss is asso-
ciated with significant side effects, then the RPB will be
smaller. The RPB, therefore, could be used to quantify
the potential overall benefit of a prevention measure
targeted to a marker or risk factor. Similar to binary
markers, if the analysis of effects for prevention and disease
detection is restricted to the diseased group only (ignore f d
xð Þ in RPB above) for a continuous marker in prevention,




η xð Þf d xð ÞdxR ∞
c
f d xð Þdxþ
R c
−∞
f d xð Þdx
, which is an estimation of pre-
vention effects with consideration of at risk subjects only,
and it will always have a positive value (benefit).
Example 7: RPB calculation for continuous markers or
risk factors. To evaluate the benefit of using a continu-
ous biomarker or risk factor for disease intervention, the
probability density distribution of the marker in the
population of disease outcome fd(x) and non-disease
outcome f d xð Þ can be estimated from observed popula-
tion data. Then, to calculate RPB of the continuous bio-
marker, a threshold c of the biomarker is chosen (i.e.,
any subjects with the biomarker level above the thresh-
old will be predicted to have the disease outcome); then
numerical integration can be used to obtain RPB for the
continuous markers using the formula above. For example,
using the same loss of quality of life adjustment factors of
the three cancers shown in Example 6 (the loss factor f2 are
0.03, 0.06, and 0.15 for the three cancers), assume the prob-
ability distributions of a continuous marker in the popula-
tion with disease fd(x) and without disease f d xð Þ follow the
normal distributions with different means as shown in
Figure 1. Using numerical integration for the RPB formula
above, we calculated the RPB for various scenarios in which
the hypothetical continuous markers have different OR for
the cancer risk as shown in Table 2. In these calculations,
the thresholds c of the continuous biomarker were chosen
to demonstrate various possibilities for outcome prediction
including fixed sensitivity, fixed specificity, and balanced
sensitivity and specificity. Table 2 shows numerical exam-
ples with assumption of 1% disease prevalence for RPB
calculation. Disease prevalence w of a population will dir-
ectly affect RPB value. For example, for a breast cancer bio-
marker with balanced sensitivity and specificity if the
disease prevalence is changed from 1% to 3%, the cor-
responding RPB values for a risk biomarker with vari-
ous OR values 1.5, 2, 4, 10, 20, and 50 will be changed
from -0.316, -0.285,-0.222, -0.137, -0.085, -0.020 for
1% prevalence to -0.12, -0.09, -0.025, 0.058, 0.112,
0.176 respectively for 3% prevalence.Discussion
With rapid advances in various technologies, a large num-
bers of biomarkers have been reported to be associated
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to the clinic and for public health benefit is a critical but
difficult next step. For example, genome-wide association
studies are identifying hundreds of SNPs associated with a
variety of diseases. While the rich discoveries from such
studies continue to prompt investigation of pathway-
targeted interventions for disease prevention and therapy
[6], it is generally believed that use of single or combined
SNP information can achieve only modest improvement in
disease risk prediction or early detection programs for indi-
viduals in the general population as compared to current
clinical screening modalities [23-27]. This underscores the
need for quantitative evaluation of both the risk and poten-
tial benefit of biomarkers since in this process many factors
need to be considered including sensitivity and specificity
of the marker used for risk prediction or targeted therapy,
disease prevalence and quantitative relationship between
biomarker levels and meaningful risk measures, cost, and
risk/benefit analyses [28-30]. In this paper, we call attention
to the need to distinguish and quantify the consequences of
false positive and false negative diagnoses of a marker for
prevention and early detection/risk prediction. The RPB es-
timation can be confounded due to the marker or risk ex-
posure. Adjustment for potential confounders in estimating
RPB need be considered.
Table 1 shows the numerical relationships between
measurements commonly used for cancer detection and
prevention. For a marker with a low prevalence, the sen-
sitivity of the marker is very low even when it has a high
OR value. Combining multiple SNP/CNV markers with
low OR values for prediction may have limited effects at
the population level, i.e. a person who carries all 10 ‘risk’
SNPs will be at high risk for the disease; however very
few people carry all 10 SNPs in the general population,
thus leading to a low PAR% value. Therefore, using such
a panel may have a low impact on disease detection or
risk prediction in the general population, although it
might be applied to the few individuals in that category.
Based on three published data sets, the numerical calcu-
lations of RPB for the three cancers are presented in
Tables 1 and 2. The calculations show that due to low
specificity of a marker and the disease intervention ac-
tion based on the prediction of the markers in the tables,
risk is larger than benefit (RPB < 0) in many cases. How-
ever, we used the loss of quality of life adjustment factor
from the three cancers in a simple way to demonstrate
the application of the RPB. The risk and benefit may be
affected by many factors such as age, time, or unknown
confounders.
Six phases are recommended for developing effective bio-
markers, with longitudinal studies considered essential for
validation [31]. Pepe et al. [32] presented a comprehensive
method for evaluating the predictiveness of a biomarker
and its performance as a disease classifier. The applicationof PAR% was evaluated for benefit of community-based ef-
forts to prevent disease using a specific cancer marker by
Wacholder [33]. Furthermore, the quantitative connection
between biomarker levels in cases and controls and clinical
meaningful risk measures or testing also has been carefully
evaluated by Wentzensen and Wacholder [30], adding a
useful tool for apprising candidate biomarkers at an early
stage. The RPB proposed in this study takes account of
both accuracy of outcome prediction of a marker and bene-
fit for a population if the marker were used for an interven-
tion. The prediction accuracy of biomarker(s) should be
assessed and compared with validated or well-established
tools (such as area under the curve, integrated discrimin-
ation improvement, net reclassification improvement etc.).
Then the value of biomarker(s) should be further evaluated
for risk and benefit if it were to be applied in a large popu-
lation for intervention. In this paper, we assumed the selec-
tion of biomarker(s) for prediction has been completed,
and we propose the RPB for risk and benefit analysis at the
population level when a given marker or risk factor is used
for disease intervention. Specifically, we concentrate on the
framework of risk/benefit analysis in using a marker for dis-
ease prevention and detection/prediction.
The 1,000 Genomes Project is expected to discover
substantially more SNP markers and other variants that
have frequency between 0.5 to 5%. Those data could be
analyzed by the methods presented in this paper. Thus
far, the performance of SNP/CNV for disease risk pre-
diction or risk stratification still needs improvement
[34], while their potential for disease prevention or tar-
geted therapy [7] and prediction of prognosis [35] is sub-
stantially encouraging. A broad risk/benefit analysis will
be needed when translating the results of such studies
into clinical use for cancer risk prediction, detection and
prevention. Greenland [36] pointed out that the eva-
luation of marker prediction models are linked to
predictor-conditional performance, cut-point choices,
and error costs; and there is a need for reorientation
toward cost-effective prediction. We extended the issue
further by distinguishing between using biomarkers for
early disease detection and using them for prevention.
The feasibility or value of using biomarkers in the two
scenarios could be generalized by risk/benefit analysis, a
research direction that has been proposed in previous
studies [37,38]. The proposed RBP for binary and con-
tinuous markers/exposures can be extended to health
economics studies.
The National Cancer Institute recently identified chal-
lenges for cancer epidemiology in the 21st century [39].
Eight overarching recommendations with corresponding
actions were proposed by the scientific community for
consideration [40]. Here, we propose methods that can
be used for assessing risk and benefit of disease inter-
vention based on a biomarkers or risk factors, which are
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tions: (1) “balance the epidemiology research portfolio
beyond traditional emphasis on discovery and etiology
research to encompass development and evaluation of
clinical and population interventions, implementation,
dissemination, and outcomes research”; and (2) “support
knowledge integration and meta research (systematic re-
views, modeling, decision analysis etc.) to identify gaps,
inform funding, and to integrate epidemiologic know-
ledge into decision making”. The RPB is intended to il-
lustrate an approach to assess the risk and potential
benefits using a marker/risk factor for intervention in
both early detection and prevention. As such, it is a gen-
eral framework, and requires a proper estimation of
‘risk/benefit’ quantifications (f1 and f2) in the RPB model
for each disease. Substantial effort may be needed to
properly estimate such parameters for a biomarker to
properly evaluate the feasibility of using the biomarkers
for different scenarios such as early detection, risk pre-
diction, and prevention.
Conclusions
Making use of the discovered biomarkers/risk factors
from epidemiological and clinical research for clinical
decision making is a key step to translate the discoveries
into practical use to achieve health benefits. Risk benefit
analysis provides crucial information for disease inter-
vention decision making. It is worthwhile to distinguish
and quantify the differences between the use of bio-
markers/risk factors to identify preventive interventions
versus their use in disease risk prediction and early de-
tection. The RPB proposed in this paper not only con-
siders the absolute risk of a disease in intervention, but
also takes into account risk-benefit effects simultan-
eously for a marker/exposure at the population level.
Using concrete examples, we demonstrate that RPB de-
veloped in this study is a useful tool for quantitatively
assessing the risk and benefits in using a biomarker/risk
factor for intervention in both early detection and
prevention.
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